<DOC>
	<DOCNO>NCT00911092</DOCNO>
	<brief_summary>The scope trial predict early complete clinical response exclusive concomitant radiochemotherapy esophageal cancer study pre- per- therapeutic proteomic profile .</brief_summary>
	<brief_title>Predictive Proteomic Factors Response Concomitant Radiochemotherapy Esophageal Cancer</brief_title>
	<detailed_description>Further information provide Centre Oscar Lambret .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Invasive esophageal carcinoma stage ( T , N0 N1 , M0 M1a ) , histologically proven Treated exclusive concomitant radiochemotherapy Written inform consent Presence second uncontrolled cancer Metastatic carcinoma Metastatic disease , except cervical lymphnodes ... ( M1a ) In situ carcinoma Esogastric junction cancer ( Siewert II ou III ) Inclusion clinical trial experimental drug study 15 week end radiotherapy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Oesophageal cancer</keyword>
	<keyword>exclusive concomitant radiochemotherapy</keyword>
</DOC>